期刊文献+

宫颈脱落细胞HPV L1蛋白及HPV DNA载量在宫颈病变中的临床意义 被引量:2

Clinical Significance of HPV L1 Protein and HPV DNA Load of Cervical Exfoliated Cells in Cervical Lesions
下载PDF
导出
摘要 目的探讨宫颈脱落细胞HPV L1蛋白及HPV DNA载量在宫颈病变中的临床意义。方法收集我院2014年5月至2016年1月的237例患者的宫颈脱落细胞标本,检测其HPV DNA载量,并对高危型HPV阳性者行HPV L1蛋白检测,分析检测结果。结果 HPV L1蛋白阳性率为21.52%(51例),正常/慢性宫颈炎、CINⅠ、CINⅡ、CINⅢ和宫颈癌患者的HPV L1蛋白阳性率比较差异有统计学意义(P<0.05)。HPV阳性率为74.26%(176例),正常/慢性宫颈炎、CINⅠ、CINⅡ、CINⅢ和宫颈癌患者的HPV阳性率比较差异有统计学意义(P<0.05)。HPV DNA载量低度组、中度组、高度组的HPV L1蛋白阳性率分别为39.22%、51.95%、77.08%,高度组的HPV L1蛋白阳性率显著高于其他两组,差异有统计学意义(P<0.05)。结论 HPV L1蛋白与HPV DNA载量对评估宫颈病变有一定作用,对其进行监测能够为宫颈病变预测、治疗及预后提供有效参考。 Objective To explore the clinical significance of HPV L1 protein and HPV DNA load of cervical exfoliated cells in cervical lesions. Methods 237 samples of cervical exfoliated ceils of patients in our hospital from May 2014 to January 2016 were collected. The HPV DNA load was detected, and the L1 HPV protein of high-risk HPV positive patients were detected. The detection results were analyzed. Results The HPV L1 protein positive rate was 21.52% (51 cases). Statistical difference was found in the HPV L1 protein positive rates of patients with normal/chronic cervicitis, C1N Ⅰ and C1N Ⅱ, C1N Ⅲ and cervical cancer (P〈0.05). The HPV positive rate was 74.26% (176 cases). Statistical difference was found in the HPV positive rates of patients with norma/chronic cervicitis, C1N Ⅰ and C1N Ⅱ, C1N Ⅲ and cervical cancer (P 〈0.05). The HPV L1 protein positive rate of low HPV DNA load group, medium group and high group were respectively 39.22%, 51.95% and 77.08%. The HPV L1 protein positive rate of high group was significantly higher than that of other groups, with statistical differences (P〈0.05). Conclusions HPV L1 protein and HPV DNA load has certain effect in the evaluation of cervical lesions. Monitoring both indicators can provide effective reference for prediction, treatment and prognosis of cervical lesions.
出处 《临床医学工程》 2017年第7期967-968,共2页 Clinical Medicine & Engineering
关键词 宫颈病变 人乳头瘤病毒(HPV) HPV DNA载量 Cervical lesions Human papilloma virus (HPV) HPV DNA load
  • 相关文献

参考文献10

二级参考文献103

  • 1吕卫国,谢幸.宫颈癌的筛查[J].中国实用妇科与产科杂志,2006,22(1):8-9. 被引量:95
  • 2Correnti M, Medina F, Cavazza ME, et al. Human papillomavirus (HPV) type distribution in cer vical carcinoma, low-grade, and high-grade squamous intraepithelial lesions in Venezuelan women[J]. Gynecol Oncol, 2011, 121(3): 527-531.
  • 3Tsai HT, Tsai YM, Yang SF, et al. A notable accessory screening program for detection of cervical intraepithelial neoplasia[J]. Pathol Biol (Paris), 2009, 57(6): 477-482.
  • 4Lorincz AT, Castle PE, Sherman ME, et al. Viral load of human papillomavirus and risk of CIN3 or cervical cancer[J]. Lancet, 2002, 360(9328): 228-229.
  • 5De Francesco MA, Gargiulo F, Schreiber C, et al. Detection and genotyping of human papillomavirus in cervical Samples from Italian patients[J]. J Med Virol, 2005, 75(4): 588-592.
  • 6Nielsen A, Kiaer SK, Munk C, et al. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women[J]. J Med Virol, 2010, 82(4): 616-623.
  • 7Boulet GA, Horvath CA, Berghmans S, et al. Human papillomavirus in cervical cancer screening: important role as biomarker[J]. Cancer Epidemiol Biomarkers Prev, 2008, 17(4): 810-817.
  • 8Arbyn M, Buntinx F, Van R anst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia[J]. J Natl Cancer Inst, 2004, 96(4): 280-293.
  • 9Cox T, Cuzick J. HPV DNA testing in cervical cancer screening: from evidence to policies[J]. Gynecol Oncol, 2006, 103(1): 8-11.
  • 10Ronco G, Segnan N, Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology in primary cervical screening: results at recruitment from the NTCC randomized controlled trail[J]. J Natl Cancer Inst, 2006, 98(11): 765-774.

共引文献97

同被引文献63

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部